| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $3,343,810 | 15 | 100 |
| Korczynski Sherry | Chief Commercial Officer | 0 | $0 | 1 | $65,687 | $-65,687 |
| Cioffi Melina | SVP, Regulatory Affairs | 0 | $0 | 1 | $105,623 | $-105,623 |
| Kraus Carl N | Chief Medical Officer | 0 | $0 | 1 | $141,904 | $-141,904 |
| BRAENDER LORI J | Chief Legal Officer | 0 | $0 | 1 | $167,346 | $-167,346 |
| TOTH A ERNEST JR | Chief Financial Officer | 0 | $0 | 1 | $243,094 | $-243,094 |
| Boyd Peter E. | See Remarks | 0 | $0 | 4 | $336,914 | $-336,914 |
| Jung Cassie | Chief Operating Officer | 0 | $0 | 3 | $975,687 | $-975,687 |
| Barber Daniel | President and CEO | 0 | $0 | 3 | $1.31M | $-1.31M |
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Over the last 12 months, insiders at Aquestive Therapeutics, Inc. have bought $0 and sold $3.34M worth of Aquestive Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aquestive Therapeutics, Inc. have bought $63,498 and sold $1.26M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $4,050 was made by Boyd Peter E. (SVP‑Bus. Process & Info. Tech.) on 2022‑06‑14.
| 2026-03-10 | Sale | Barber Daniel | President and CEO | 180,677 0.177% | $4.17 | $753,965 | -4.87% | |
| 2026-03-10 | Sale | BRAENDER LORI J | Chief Legal Officer | 40,102 0.0393% | $4.17 | $167,346 | -4.87% | |
| 2026-03-10 | Sale | TOTH A ERNEST JR | Chief Financial Officer | 58,254 0.0571% | $4.17 | $243,094 | -4.87% | |
| 2026-03-10 | Sale | Boyd Peter E. | Chief People Officer | 29,814 0.0292% | $4.17 | $124,414 | -4.87% | |
| 2026-03-10 | Sale | Jung Cassie | Chief Operating Officer | 45,791 0.0449% | $4.17 | $191,086 | -4.87% | |
| 2026-03-10 | Sale | Cioffi Melina | SVP, Regulatory Affairs | 25,311 0.0248% | $4.17 | $105,623 | -4.87% | |
| 2026-03-10 | Sale | Korczynski Sherry | Chief Commercial Officer | 15,741 0.0154% | $4.17 | $65,687 | -4.87% | |
| 2025-10-15 | Sale | Kraus Carl N | Chief Medical Officer | 20,272 0.0194% | $7.00 | $141,904 | -41.86% | |
| 2025-10-15 | Sale | Boyd Peter E. | See Remarks | 10,000 0.0096% | $7.00 | $70,000 | -41.86% | |
| 2025-10-15 | Sale | Jung Cassie | Chief Operating Officer | 67,575 0.0647% | $7.01 | $473,701 | -41.86% | |
| 2025-09-26 | Sale | Barber Daniel | President and CEO | 91,343 0.0923% | $6.03 | $551,191 | -10.02% | |
| 2025-09-26 | Sale | Boyd Peter E. | See Remarks | 10,000 0.0105% | $6.30 | $63,000 | -10.02% | |
| 2025-09-19 | Sale | Barber Daniel | President and CEO | 400 0.0004% | $6.00 | $2,400 | -5.73% | |
| 2025-09-05 | Sale | Boyd Peter E. | See Remarks | 15,000 0.0147% | $5.30 | $79,500 | -4.89% | |
| 2025-09-04 | Sale | Jung Cassie | Chief Operating Officer | 62,180 0.0616% | $5.00 | $310,900 | +2.17% | |
| 2024-11-26 | Sale | Jung Cassie | Chief Operating Officer | 44 <0.0001% | $4.87 | $214 | -26.74% | |
| 2024-03-15 | Sale | Schobel Alexander Mark | Chief Innovation/Tech Officer | 50,000 0.0672% | $6.00 | $300,000 | -40.23% | |
| 2024-03-08 | Sale | Schobel Alexander Mark | Chief Innovation/Tech Officer | 25,000 0.0364% | $5.19 | $129,685 | -23.36% | |
| 2022-06-14 | Boyd Peter E. | SVP-Bus. Process & Info. Tech. | 5,000 0.0107% | $0.81 | $4,050 | +11.38% | ||
| 2022-06-08 | Schobel Alexander Mark | Chief Innovation/Tech Officer | 45,871 0.1074% | $0.96 | $44,036 | +2.89% |
| Barber Daniel | President and CEO | 1004753 1.0118% | $4.34M | 2 | 3 | <0.0001% |
| BRAENDER LORI J | Chief Legal Officer | 442879 0.446% | $1.91M | 4 | 1 | +53.97% |
| TOTH A ERNEST JR | Chief Financial Officer | 376112 0.3787% | $1.62M | 0 | 1 | |
| Boyd Peter E. | Chief People Officer | 338509 0.3409% | $1.46M | 5 | 4 | +43.71% |
| Kraus Carl N | Chief Medical Officer | 282475 0.2844% | $1.22M | 0 | 1 | |
| Jung Cassie | Chief Operating Officer | 274980 0.2769% | $1.19M | 0 | 4 | |
| Cioffi Melina | SVP, Regulatory Affairs | 274867 0.2768% | $1.19M | 0 | 1 | |
| Korczynski Sherry | Chief Commercial Officer | 241117 0.2428% | $1.04M | 0 | 1 | |
| Schobel Alexander Mark | Chief Innovation/Tech Officer | 984476 0.9913% | $4.25M | 4 | 9 | <0.0001% |
| Kendall Keith J | 638964 0.6434% | $2.76M | 6 | 1 | <0.0001% | |
| BRATTON DOUGLAS K | 165000 0.1662% | $712,800.00 | 1 | 0 | <0.0001% | |
| Maxwell John T. | 150614 0.1517% | $650,652.48 | 2 | 1 | <0.0001% | |
| Wood Theresa | 80765 0.0813% | $348,904.80 | 2 | 0 | <0.0001% | |
| Scibetta James S | 31635 0.0319% | $136,663.20 | 3 | 0 | +13.42% | |
| Marshall Ken W. | 1445 0.0015% | $6,242.40 | 1 | 0 | <0.0001% |
$218,350,131 | 64 | 16.68% | $424.13M | |
$129,489,279 | 57 | 26.09% | $321.6M | |
$2,767,882 | 51 | 8.70% | $49.58M | |
$102,709,455 | 46 | 30.55% | $1.06B | |
$33,884,330 | 45 | 12.58% | $341.03M | |
$97,642,477 | 41 | -10.58% | $305.13M | |
$11,542,910 | 40 | 56.19% | $1.55B | |
Aquestive Therapeutics, Inc. (AQST) | $6,021,989 | 30 | -0.17% | $429M |
$32,539,771 | 28 | 33.37% | $157.01M | |
$6,506,230 | 27 | -16.20% | $1.03B | |
$25,034,841 | 20 | 9.38% | $722.35M | |
$1,843,996 | 10 | 22.92% | $1.05B | |
$26,633,903 | 9 | 42.23% | $1.09B | |
$758,061 | 9 | 60.03% | $132.05M | |
$1,718,514 | 9 | 38.13% | $799.52M | |
$179,515 | 7 | 1.51% | $456.1M | |
$721,578 | 7 | -19.64% | $579.17M | |
$208,823 | 7 | -1.10% | $116.08M | |
$12,300,713 | 4 | 24.14% | $201.63M |
| Increased Positions | 113 | +77.4% | 15M | +22.43% |
| Decreased Positions | 61 | -41.78% | 9M | -13.21% |
| New Positions | 45 | New | 4M | New |
| Sold Out Positions | 23 | Sold Out | 2M | Sold Out |
| Total Postitions | 198 | +35.62% | 72M | +9.22% |
| Bratton Capital Management, L.P. | $63,281.00 | 8.04% | 9.81M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $42,091.00 | 5.35% | 6.53M | +49,077 | +0.76% | 2025-09-30 |
| Rtw Investments, Lp | $40,313.00 | 5.12% | 6.25M | +6M | New | 2025-09-30 |
| Vanguard Group Inc | $36,521.00 | 4.64% | 5.66M | +1M | +30.81% | 2025-09-30 |
| Perceptive Advisors Llc | $24,253.00 | 3.08% | 3.76M | +2M | +71.66% | 2025-09-30 |
| Ecor1 Capital, Llc | $16,931.00 | 2.15% | 2.63M | +3M | New | 2025-09-30 |
| Samsara Biocapital, Llc | $16,125.00 | 2.05% | 2.5M | +3M | New | 2025-09-30 |
| Geode Capital Management, Llc | $13,467.00 | 1.71% | 2.09M | +110,947 | +5.61% | 2025-09-30 |
| State Street Corp | $10,334.00 | 1.31% | 1.6M | +94,918 | +6.3% | 2025-09-30 |
| Sio Capital Management, Llc | $9,663.00 | 1.23% | 1.5M | +550,606 | +58.11% | 2025-09-30 |